5292092
Last Update Posted: 2026-01-21
Recruiting has ended
All Genders accepted | 18 Years + |
161 Estimated Participants | No Expanded Access |
Observational Study | Does not accept healthy volunteers |
Essential Pro PMCF Study ( rEPIC04E )
Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Essential Pro to meet EU Medical Device regulation (MDR) requirements in all the CONSECUTIVE patients treated with Essential Pro.
The objective of this multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study is to confirm and support the clinical safety and performance of the Essential Pro in a NON-SELECTED, Real World population under daily clinical practice when used as intended by the manufacturer to meet EU Medical Device regulation requirements for post-market clinical follow-up.
Eligibility
Relevant conditions:
Coronary Artery Disease (CAD)
Ischemic Heart Disease
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
FUNDACION EPIC
iepic@fundacionepic.org
987225638
FUNDACION EPIC
admin@fundacionepic.org
987225638
Data sourced from ClinicalTrials.gov